Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Artigo em Russo | MEDLINE | ID: mdl-20737708

RESUMO

The present work was designed to study the expression of CD95 antigen (Fas/APO-1) at the surface of neutrophil granulocytes from the cervical secretion. Sixty five female patients with Chlamydia infection available for observation exhibited enhanced CD95+ expression following basic therapy. It was found that combined treatment with the use of magnetic laser radiation normalized the level of CD95+ surface receptors on neutrophils.


Assuntos
Infecções por Chlamydia , Regulação da Expressão Gênica , Terapia a Laser , Magnetoterapia , Neutrófilos/metabolismo , Doenças do Colo do Útero , Receptor fas/biossíntese , Adulto , Colo do Útero/metabolismo , Colo do Útero/microbiologia , Infecções por Chlamydia/metabolismo , Infecções por Chlamydia/microbiologia , Infecções por Chlamydia/terapia , Feminino , Humanos , Doenças do Colo do Útero/metabolismo , Doenças do Colo do Útero/microbiologia , Doenças do Colo do Útero/terapia
2.
Arch Med Res ; 26 Spec No: S149-52, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8845640

RESUMO

A prospective study to evaluate the role of vitamin C and cervico-vaginal infection in the premature rupture of amniotic membranes (PROM) was designed. The leukocyte vitamin C levels of 44 pregnant women that did not consume vitamin supplements was evaluated at weeks 20, 28 and 32 of pregnancy. On each evaluation the presence of cervico-vaginal infection was diagnosed and treated. The leukocyte vitamin C level throughout gestation showed a decrease towards week 28 and then it recovered at the end of pregnancy. Six of every ten women had normal flora in their vaginal secretion cultures. Eleven cases had PROM (0.24), no association was found between cervico-vaginal infection and PROM. The leukocyte vitamin C levels on week 20 of gestation showed an association with PROM. (chi 2 = 6.34, p < 0.05, odds ratio 6.75 [CI 1.26-26.03]).


Assuntos
Deficiência de Ácido Ascórbico/complicações , Infecções Bacterianas/complicações , Candidíase/complicações , Ruptura Prematura de Membranas Fetais/etiologia , Doenças do Colo do Útero/etiologia , Doenças Vaginais/etiologia , Adulto , Estudos de Casos e Controles , Feminino , Ruptura Prematura de Membranas Fetais/microbiologia , Humanos , Gravidez , Estudos Prospectivos , Doenças do Colo do Útero/microbiologia , Doenças Vaginais/microbiologia
3.
Sex Transm Dis ; 21(4): 213-6, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7974072

RESUMO

BACKGROUND AND OBJECTIVES: Due to the steadily progressive development of resistance to the drugs used for treatment, Neisseria gonorrhoeae remains a medical concern. Trospectomycin sulfate is a 6' propyl analogue of spectinomycin with potent activity against penicillin sensitive and resistant strains of N. gonorrhoeae. GOAL OF THIS STUDY: To compare the efficacy of 250 mg trospectomycin sulfate i.m. versus 250 mg ceftriaxone i.m. for single dose therapy for men and women with uncomplicated gonorrhea. STUDY DESIGN: Dual-center, randomized comparative trial. RESULTS: Among evaluable male patients with urethral gonorrhea, 36 of 40 (90%, 95% confidence interval [95%CI] 76%-97%) who were treated with trospectomycin sulfate were cured, and 22 of 22 patients (100%, [85%-100%]) treated with ceftriaxone were cured. Among evaluable female patients with cervical gonorrhea all were cured following trospectomycin sulfate (23 of 23) and following ceftriaxone therapy (13 of 13). The cure rates for pharyngeal gonorrhea were 67% (8 of 12 patients, 35%-90%) for trospectomycin sulfate therapy, and 100% (2 of 2) with ceftriaxone therapy. CONCLUSIONS: Trospectomycin sulfate, 250 mg i.m., is effective, and well tolerated. However, for treatment of uncomplicated genital and pharyngeal gonorrhea, it is not as reliable for therapy as other recommended regimens.


Assuntos
Ceftriaxona/uso terapêutico , Gonorreia/tratamento farmacológico , Doenças Faríngeas/tratamento farmacológico , Espectinomicina/análogos & derivados , Doenças Uretrais/tratamento farmacológico , Doenças do Colo do Útero/tratamento farmacológico , Intervalos de Confiança , Resistência Microbiana a Medicamentos , Feminino , Seguimentos , Gonorreia/microbiologia , Humanos , Injeções Intramusculares , Masculino , Testes de Sensibilidade Microbiana , Doenças Faríngeas/microbiologia , Espectinomicina/uso terapêutico , Resultado do Tratamento , Doenças Uretrais/microbiologia , Doenças do Colo do Útero/microbiologia
4.
Eur J Clin Microbiol Infect Dis ; 11(8): 693-7, 1992 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1330565

RESUMO

The efficacy of single-dose azithromycin therapy in the treatment of cervical Chlamydia trachomatis infections was compared to that of a standard seven-day course of treatment with doxycycline. Cervical samples from 60 patients reacted positively in an enzyme immunoassay for detection of Chlamydia trachomatis. In 31 patients Chlamydia trachomatis was isolated from the sample taken before treatment. Fourteen of the 31 patients were treated with doxycycline and 17 with azithromycin. All cultures of samples taken one and four weeks after the start of therapy were negative. All 31 isolates showed a similar pattern of MICs for the seven antibiotics tested, including azithromycin and doxycycline. No differences were observed between isolates of different serovars. In samples from four patients chlamydial DNA could be detected by PCR one week after the start of the therapy and in two patients also after four weeks. No difference in microbiological parameters could be observed between the two treatment groups. It is concluded that single-dose azithromycin is as effective as a seven-day course of doxycycline in the therapy of cervical Chlamydia trachomatis infections.


Assuntos
Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis/isolamento & purificação , Doxiciclina/uso terapêutico , Eritromicina/análogos & derivados , Doenças do Colo do Útero/tratamento farmacológico , Azitromicina , Sequência de Bases , Doxiciclina/administração & dosagem , Esquema de Medicação , Eritromicina/administração & dosagem , Eritromicina/uso terapêutico , Feminino , Humanos , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Doenças do Colo do Útero/microbiologia
5.
Sex Transm Dis ; 14(4): 195-200, 1987.
Artigo em Inglês | MEDLINE | ID: mdl-3438783

RESUMO

During prospective studies of infants born vaginally to women with cervical Chlamydia trachomatis infection, we evaluated 27 infants given 0.5% erythromycin ointment and 93 given 1% silver nitrate solution as eye prophylaxis, according to the preference of the parents or delivery room personnel. The cumulative proportion of infants developing chlamydial conjunctivitis was 25% for both groups (P = 0.37, Mantel-Cox test). The cumulative proportion of infants developing chlamydial infection at any anatomic site was 74% for those given erythromycin and 70% for those given silver nitrate (P = 0.93). The two groups did not differ significantly in cumulative proportions developing nonchlamydial conjunctivitis. These results indicate that, as it is routinely used in our hospital, erythromycin ointment was not more effective than silver nitrate as prophylaxis against chlamydial conjunctivitis. The influence of delayed administration on efficacy of prophylaxis requires further evaluation.


Assuntos
Infecções por Chlamydia/prevenção & controle , Conjuntivite/prevenção & controle , Eritromicina/uso terapêutico , Nitrato de Prata/uso terapêutico , Infecções por Chlamydia/microbiologia , Chlamydia trachomatis/isolamento & purificação , Feminino , Humanos , Lactente , Recém-Nascido , Pomadas , Soluções Oftálmicas , Gravidez , Complicações Infecciosas na Gravidez/microbiologia , Doenças do Colo do Útero/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA